GSTP1 and benign prostatic hyperplasia: Two variables that distinguished PCa, as derived from the targeted BS-seq experiments, were found to be significantly differently represented between normal and cancerous samples in the WGBS experiments, namely, GSTP1.T5.T9 (88.6/99.1%—averages in the PCa/healthy and BPH groups, targeted BS-seq; 15.0/54.5%—positive in the cancer/normal groups according to WGBS) and GSTP1.C9 (8.35/0.160%—averages in the PCa/healthy and BPH groups according to the targeted BS-seq; 79.9/51.8%—positive in the cancer/normal groups according to WGBS) (Table S6).